Akcea Therapeutics (AKCA) Stock Price, News & Analysis

Company Overview

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Key Stats

• Today's Range: $18.17 to $18.17
• 50-Day Range: $18.13 to $18.17
• 52-Week Range: $8.00 to $21.70
• Volume: N/A
• Average Volume: 361,806 shs
• Market Capitalization: $1.85 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AKCA Stock Analysis - Frequently Asked Questions

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics, Inc. (NASDAQ:AKCA) issued its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.14. The business's revenue was down 15.9% compared to the same quarter last year.

When did Akcea Therapeutics IPO?

Akcea Therapeutics (AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Advanced Micro Devices (AMD), Ciena (CIEN), Fossil Group (FOSL) and AMC Entertainment (AMC).

Company Calendar

• Last Earnings: 8/04/2020
• Today: 2/23/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AKCA
• CUSIP: N/A
• CIK: 1662524
• Web: www.akceatx.com
• Phone: 617-207-0202
• Fax: N/A
• Employees: 248
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.48
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $40.77 million
• Net Margins: -12.34%
• Pretax Margin: N/A
• Return on Equity: -8.94%
• Return on Assets: -8.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.17
• Quick Ratio: 11.78

Sales & Book Value

• Annual Sales: $488.54 million
• Price / Sales: 3.78
• Cash Flow: $0.51 per share
• Price / Cash Flow: 35.54
• Book Value: $5.78 per share
• Price / Book: 3.14

Miscellaneous

• Outstanding Shares: 101,599,000
• Free Float: N/A
• Market Cap: $1.85 billion
• Optionable: Optionable
• Beta: 1.45